The influence of the maintenance of physical activity on mental health of patients with occupational lung diseases after an inpatient rehabilitation in the BG clinic of Falkenstei

Not Applicable

• Conditions: J61; J44; J60; J67; J68; J45; J92; J95; Pneumoconiosis due to dust containing silica; Pneumoconiosis due to asbestos and other mineral fibres

• Registration Number: DRKS00010777
• Lead Sponsor: Deutsche Gesetzliche Unfallversicherung e. V.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-12-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 194

Inclusion Criteria

recognised occupational diseases (lung and respiratory diseases: BK 4101,BK 4103, BK 4111, BK 4301, BK 4302, BK 1315)

Exclusion Criteria

- none of the recognised occupational diseases
- (occupational) oncological diseases in the last 2 years
- pronounced limitations of the cardiovascular and musculoskeletal system
- cognitive deficits, language misunderstandings
- physically active persons (if regularly at least two times a week for at least 30 min)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome is the physical active level, which is assessed by activity monitors (ActiGraphGT3x+®) and the questionnaire PROactive visit questionnaire clinical version. These data will be collected three weeks before the start of rehabilitation as well as two, six and twelve months after rehabilitation.

Secondary Outcome Measures

Name	Time	Method
Further mental health and other relevant parameters that are associated with physical activity will be assessed three weeks before the start of rehabilitation as well as two, six and twelve months after rehabilitation. These include physical Fitness (Six-Minutes-Walktest), quality of life (Chronic Respiratory Questionnaire), self-efficacy (COPD Self-efficacy Scale), Motivation (Questionnaire for motivational Self-efficacy), depressive symptoms and anxiety (Hospital Anxiety and Depression Scale, COPD Anxiety Questionnaire).<br><br>